Takeda Oncology
Matt Hewlett is an experienced professional in the pharmaceutical and oncology industries, currently serving as Associate Director of Alliance Management at Takeda Oncology since May 2023. Prior roles include Associate Director of Global Corporate and Business Development at Rakuten Medical and Product Manager for US Solid Tumor Marketing at Sanofi Genzyme. Hewlett also held positions focused on global commercial strategy and marketing, alongside experience as Adjunct Faculty and PharmD Fellow at Massachusetts College of Pharmacy and Health Sciences. Education includes a Doctor of Pharmacy (PharmD) and a Master of Business Administration (M.B.A.) from the University of Kentucky.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.